Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge
Massachusetts
02142
United States
Tel: 617-491-9700
Fax: 617-621-0431
Website: http://www.momentapharma.com/
Email: info@momentapharma.com
About Momenta Pharmaceuticals, Inc.
Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.
In April 2015, Momenta announced the FDA approval of once daily Glatopa™ (glatiramer acetate injection), a fully substitutable generic version of Copaxone® 20 mg/mL. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second complex generic developed by Momenta to receive FDA approval.
In July 2010, Momenta announced the FDA approval of our first drug, Enoxaparin Sodium Injection developed in collaboration with Sandoz.
360 articles about Momenta Pharmaceuticals, Inc.
-
Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.
-
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
-
Top 2020 Biopharma M&A Deals
1/6/2021
BioSpace highlights a number of the key M&A deals struck over the past 12 months. -
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson
10/1/2020
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion. The all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary of Johnson & Joh
-
Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson
9/15/2020
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with the all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary
-
SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.
8/19/2020
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc. ("MNTA" or the "Company") (NASDAQ: MNTA) in conne
-
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
8/19/2020
Lead Asset Nipocalimab Provides Opportunity for Janssen to Deliver Transformative Treatments in Autoantibody-Driven Autoimmune Diseases
-
Momenta Enters Definitive Agreement with Johnson & Johnson
8/19/2020
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020
-
J&J said the acquisition will allow its subsidiary, Janssen Pharmaceutical, to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease.
-
Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results
8/10/2020
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the second quarter ended June 30, 2020.
-
Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast
8/3/2020
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020. Management will host a conference call on August 10, 2020 at 8:30 a.m. ET to discuss these results
-
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
7/28/2020
Momenta Pharmaceuticals, Inc. announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration for the prevention of hemolytic disease of the fetus and newborn.
-
Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
6/15/2020
Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001)
-
Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results
5/7/2020
Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, reported its financial results for the first quarter ended March 31, 2020.
-
Momenta Pharmaceuticals Announces Date of First Quarter 2020 Financial Results Conference Call and Webcast
4/23/2020
Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced that it will release its financial results for the first quarter ended March 31, 2020 before the U.S. financial markets open on Thursday, May 7, 2020..
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Momenta Provides Corporate Update Amid COVID-19 Pandemic
4/2/2020
Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, provided an update on the Company’s clinical trial activities and business operations in light of the COVID-19 pandemic.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2/26/2020
-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 -- -- Target enrollment completed in nipocalimab Phase 2 Vivacity-MG study; top-line proof-of-concept results expected in Q3 2020 -- -- Expanded pipeline with nomination of M267, a new SIFbody development candidate targeting CD38; plan to initiate IND-enabling studies in 2020 -- -- Ended 2